WHAT IS HATCH WAXMAN?
The Hatch-Waxman Act, passed in 1984, is a Congress-enacted framework aimed to expedite generic pharmaceutical approvals, maintain innovation incentives and introduce a procedure for litigation concerning generic drugs, establishing the foundation for the modern generic pharmaceutical industry.
INTREPID HATCH WAXMAN FOCUS AND EXPERTISE
Intrepid’s Managed Review solution places a significant emphasis on the Pharmaceutical Sector, particularly legal cases arising from the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act. Our tenured team possesses substantial knowledge, expertise and deep understanding of the crucial elements within the pharmaceutical field having completed multiple matters for our clients, hence reducing / eliminating the need for training and clarity.
Leveraging our extensive technical expertise, Intrepid’s Hatch Waxman managed document review teams have a rich history completing matters within short timeframes and limited budgets, typically yielding results 30% lower than industry standard costs.
- Retaining attorneys motivated by team culture
- Encouraging creative collaboration for insights
- Leveraging extensive industry experience
- Using metrics to drive decision making
DOWNLOAD BROCHURE
EXPERTISE
- Paragraph III
- Paragraph IV
- FTF
- FTM
- NDA
- ANDA
- API
BENEFITS
- Highly experienced review team
- Advanced Hatch Waxman knowledge
- 40-100 reviews done by each reviewer
- Agile, responsive and expeditious results
- Multi-lingual reviewers and capabilities
- Minimal training or explanations needed
LET’S CONNECT
Available to listen anytime, feel free to engage with us at 858.284.4140, sales@intrepidmanageddiscovery.com or via the contact form below to let us know how we might be of assistance. We look forward to the opportunity to exceed expectations and forge a long-term relationship with your organization.